High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies

被引:84
作者
Drouart, M
Saas, P
Billot, M
Cedoz, JP
Tiberghien, P
Wendling, D
Toussirot, É
机构
[1] Univ Hosp Jean Minjoz, Dept Rheumatol, F-25030 Besancon, France
[2] INSERM, UPRES EA 2284, Dept Immunol, Besancon, France
关键词
angiogenesis; bone formation; spondylarthropathies; VEGF;
D O I
10.1046/j.1365-2249.2003.02101.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Angiogenesis is involved in chronic inflammatory joint diseases such as rheumatoid arthritis (RA). Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis. The spondylarthropathies (SpA) are characterized by enthesitis and synovitis, in which blood vessels participate. The objective of this study was to investigate serum VEGF levels and their potential associations with disease activity markers for SpA. Sera were collected from 105 patients with SpA (72 with ankylosing spondylitis (AS), four with psoriatic arthritis (PsA), six with reactive arthritis (ReA), eight with enteropathic arthropathy and 15 with undifferentiated SpA), 50 patients with rheumatoid arthritis (RA) and 64 healthy controls. Disease activity in SpA patients was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and laboratory parameters of inflammation [erythrocyte sedimentation rate (ESR) and C-reactive protein level (CRP)]. Serum VEGF levels were significantly higher in SpA patients (316.4 +/- 215.6 pg/ml) and RA patients (405.2 +/- 366.5) than in controls (217.3 +/- 145.2) (P = 0.003). In SpA patients, serum VEGF levels correlated with disease activity indices (BASDAI: r = 0.22, P = 0.04; ESR: r = 0.3, P = 0.003; and CRP: r = 0.23, P = 0.02). Serum VEGF levels were not associated with presence of extra-articular manifestations or syndesmophytes or with the grade of sacroiliitis. These results suggest that VEGF and therefore angiogenesis may play a role in SpA pathogenesis and may serve as a disease activity marker in SpAs.
引用
收藏
页码:158 / 162
页数:5
相关论文
共 29 条
  • [1] Amoroso A, 1997, Eur Rev Med Pharmacol Sci, V1, P17
  • [2] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
    ARNETT, FC
    EDWORTHY, SM
    BLOCH, DA
    MCSHANE, DJ
    FRIES, JF
    COOPER, NS
    HEALEY, LA
    KAPLAN, SR
    LIANG, MH
    LUTHRA, HS
    MEDSGER, TA
    MITCHELL, DM
    NEUSTADT, DH
    PINALS, RS
    SCHALLER, JG
    SHARP, JT
    WILDER, RL
    HUNDER, GG
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
  • [3] Baeten D, 2001, ARTHRITIS RHEUM-US, V44, P186, DOI 10.1002/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO
  • [4] 2-B
  • [5] New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders
    Ballara, SC
    Miotla, JM
    Paleolog, EM
    [J]. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 1999, 80 (05) : 235 - 250
  • [6] USE OF IMMUNOHISTOLOGIC AND IN-SITU HYBRIDIZATION TECHNIQUES IN THE EXAMINATION OF SACROILIAC JOINT BIOPSY SPECIMENS FROM PATIENTS WITH ANKYLOSING-SPONDYLITIS
    BRAUN, J
    BOLLOW, M
    NEURE, L
    SEIPELT, E
    SEYREKBASAN, F
    HERBST, H
    EGGENS, U
    DISTLER, A
    SIEPER, J
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (04): : 499 - 505
  • [7] Calin A, 1998, SPONDYLARTHRITIDES, P1
  • [8] THE EUROPEAN-SPONDYLARTHROPATHY-STUDY-GROUP PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SPONDYLARTHROPATHY
    DOUGADOS, M
    VANDERLINDEN, S
    JUHLIN, R
    HUITFELDT, B
    AMOR, B
    CALIN, A
    CATS, A
    DIJKMANS, B
    OLIVIERI, I
    PASERO, G
    VEYS, E
    ZEIDLER, H
    [J]. ARTHRITIS AND RHEUMATISM, 1991, 34 (10): : 1218 - 1227
  • [9] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE
    FOLKMAN, J
    [J]. NATURE MEDICINE, 1995, 1 (01) : 27 - 31
  • [10] GARRETT S, 1994, J RHEUMATOL, V21, P2286